Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Rury Holman has congratulated the ACE team on reaching the 6,500 randomised target.

The aim of the Acarbose Cardiovascular Evaluation (ACE) clinical trial is to establish if a drug called acarbose can prevent people with coronary heart disease and impaired glucose tolerance (IGT) from experiencing, or dying from, further heart attacks and strokes.  The ACE Trial is also looking to see if acarbose, which reduces blood glucose following a meal, can prevent or delay people progressing from IGT to type 2 diabetes.  This is a phase IV multinational trial which began in 2008.  It is being conducted in around 150 hospitals in mainland China and Hong Kong.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Doug Higgs awarded the 2023 Genetics Society Medal

The award recognises Professor Higgs' major contribution to our understanding of how mammalian genes are switched on and off, and using haematopoiesis as a model to understand how genes function.

2022 RDM Graduate Prize Winners

This year's winners are Edward Jenkins, Antje Rottner, and Akshay Shah.

KJ Patel appointed new Chief Scientist of CRUK

Alongside his new role at Cancer Research UK, Prof. Patel will continue as the Director of both the MRC Weatherall Institute for Molecular Medicine (MRC WIMM) and the MRC Molecular Haematology Unit (MRC MHU).

Anjali Kusumbe receives the RMS Life Sciences Medal

The Royal Microscopical Society awards celebrate the best in microscopy, recognising those making a special contribution to microscopy, cytometry and imaging.

Enterprise Associate Interview with Dr Shilpa Nagarajan

Dr Shilpa Nagarajan is one of the MPLS Enterprise and Innovation Fellows for 2022-23.